Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the randomized IMpower150 and IMpower130 studies in chemotherapy-naïve patients with nonsquamous metastatic NSCLC. In IMpower150, ABCP prolonged progression-free survival (PFS) and overall survival (OS) relative to BCP, regardless of EGFR or ALK status, liver metastases at baseline or PD-L1 expression levels. In IMpower130, ACnP prolonged PFS and OS relative to CnP in patients without EGFR or ALK genetic aberrations. ABCP and ACnP had manageable tolerability profiles, which were consistent with the profile of the individual components of the regimen. Immune-related adverse events with ABCP and ACnP were largely mild or moderate in severity, and most were reversible with interruption of atezolizumab and initiation of appropriate treatment. Current evidence indicates that ABCP and ACnP are valuable emerging first-line treatment options for metastatic nonsquamous NSCLC.
During the peer review process the manufacturer of atezolizumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Sohita Dhillon and Yahiya Syed are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
- 4.Huang Q, Zhang H, Hai J, et al. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology. 2018;7(12):e1396403.CrossRefGoogle Scholar
- 11.Dumoulin D, De Goeje P, Poncin M, et al. Paclitaxel/carboplatin/bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors [abstract no. 22P]. Ann Oncol. 2019;30(Suppl 2):ii7.Google Scholar
- 12.Roche. Tecentriq (atezolizumab): EU summary of product characteristics. 2019. https://www.ema.europa.eu. Accessed 8 July 2019.
- 13.Genentech Inc. TECENTRIQ® (atezolizumab): US prescribing information. 2019. https://www.gene.com. Accessed 8 July 2019.
- 14.Chugai Pharmaceutical Co. Ltd. Tecentric intravenous infusion 840 mg/1200 mg: Japanese prescribing information. 2019. http://www.pmda.go.jp. Accessed 11 Oct 2019.
- 19.Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401.CrossRefGoogle Scholar
- 20.West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37.CrossRefGoogle Scholar
- 24.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (Version 7). 2019. https://www.nccn.org. Accessed 2 Oct 2019.
- 25.National Institute of Health and Care Excellence. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. 2019. https://www.nice.org.uk. Accessed 8 July 2019.
- 30.Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) [abstract no. LBA54]. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy424.066.CrossRefPubMedGoogle Scholar
- 34.Criss SD, Mooradian MJ, Watson TR, et al. Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States. JAMA Netw Open. 2019. https://doi.org/10.1001/jamanetworkopen.2019.11952.CrossRefPubMedPubMedCentralGoogle Scholar